You are here: Home: Audio Program Guide: CCU 2 | 2007: CCU 2 | 2007 Audio
 
  Go to interview with John L Marshall , MD
Go to interview with Leonard B Saltz , MD
Go to interview with James Cassidy , MD
Point-Counterpoint: Adjuvant Therapy of Stage II Colon Cancer
  To listen to individual tracks, click the on the headphone.
To download tracks, right-click on the one you wish to download.
Wolff, MD John L Marshall , MD
Chief, Hematology and Oncology
Director of Developmental Therapeutics and GI Oncology
Lombardi Comprehensive Cancer Center
Georgetown University


  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Use of bevacizumab after discontinuation of chemotherapy or beyond disease progression
Track 3 Incorporation of panitumumab into clinical practice
Track 4 Infusion reactions with cetuximab versus panitumumab
Track 5 Treatment of potentially curable metastatic disease
Track 6 Management of synchronous primary and metastatic disease
Track 7 Patient acceptance of cetuximab-associated rash in trials of adjuvant therapy
Track 8 Capecitabine alone or with oxaliplatin for the treatment of Stage II disease
Track 9 Treatment of lower-risk breast and colon cancer
Track 10 Patient acceptance of adjuvant therapy for modest benefits
Track 11 Patient expectations about chemotherapy side effects
Track 12 A physician’s experience with a spouse being treated for breast cancer
Track 13 Impact of a personal experience with cancer on the practice of oncology
Track 14 Communication and children’s coping with a parent’s cancer
Track 15 The personal decision to participate in a clinical trial
Track 16 Impact of cancer diagnosis and treatment on lifestyle and relationships
Track 17 A personal perspective on the pace of progress in cancer research
     
Saltz, MD Leonard B Saltz , MD
Professor of Medicine
Weill Medical College of Cornell University
Attending Physician
Colorectal Disease Management Team Leader
Memorial Sloan-Kettering Cancer Center


  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 XELOX-1/NO16966: CAPOX or FOLFOX4 with or without bevacizumab as first-line therapy
Track 3 Continuation of therapy until progression on a first-line trial of IFL with or without bevacizumab
Track 4 Impact of the addition of bevacizumab to chemotherapy on response rate
Track 5 Clinical implications of XELOX-1/NO16966 and the use of CAPOX
Track 6 Evaluating alternative schedules of capecitabine
Track 7 Clinical implications of XELOX-1/NO16966 and the use of bevacizumab in combination with first-line chemotherapy
Track 8 Use of chemotherapy holidays
Track 9 Safety of a 10-minute infusion of bevacizumab
Track 10 Phase I study of the oral agent S-1 in combination with oxaliplatin and bevacizumab in patients with advanced solid tumors
Track 11 Evaluation of routine antihistamine premedication after the first two doses of cetuximab
Audio
Track 12 Geographic variation in cetuximab-associated infusion reactions
Audio
Track 13 Pharmacokinetics of cetuximab administered every two weeks
Audio
Track 14 Studies evaluating chemotherapy/bevacizumab with or without tyrosine kinase EGFR inhibitors
Audio
Track 15 Predictors of response to tyrosine kinase EGFR inhibitors
Audio
Track 16 Impact of physical activity on colon cancer recurrence and survival
Audio
     
Cassidy, MD James Cassidy , MD
Cancer Research UK Professor of Oncology
Academic Head of Centre for Oncology and Applied Pharmacology
Division of Cancer Sciences and Molecular Pathology
University of Glasgow


  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 XELOX-1/NO16966: CAPOX or FOLFOX4 with or without bevacizumab as first-line therapy
Track 3 Comparable efficacy and tolerability of CAPOX and FOLFOX
Track 4 Geographic variation in the tolerability of fluoropyrimidines
Track 5 Potential impact of discontinuing bevacizumab and chemotherapy concomitantly before progression
Track 6 Continuation of bevacizumab with a fluoropyrimidine after discontinuation of oxaliplatin off protocol
Track 7 Role of xaliproden as a neuroprotectant during oxaliplatin administration
Track 8 Efficacy of xaliproden in the prevention of and recovery from neuropathy
Track 9 AVANT adjuvant trial: FOLFOX with or without bevacizumab or CAPOX with bevacizumab
Track 10 Bevacizumab and long-term safety
Track 11 Potential advantages of panitumumab, a fully humanized monoclonal antibody against EGFR
Track 12 Incorporation of combination biologic therapies in adjuvant clinical trials
Track 13 Oral small-molecule pan-VEGFR tyrosine kinase inhibitor AZ2171
Track 14 Novel agents in development for colorectal cancer

     
  Point-Counterpoint: Adjuvant Therapy of Stage II Colon Cancer  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Incremental increases in toxicity in adjuvant treatments for Stage II disease
Track 3 Improvements in the absolute benefits associated with adjuvant therapy for Stage II disease
Track 4 Comparison of adjuvant therapy benefits for patients with Stage II and Stage III disease
Track 5 Use of molecular markers to predict outcome from treatment with adjuvant oxaliplatin and bevacizumab
Track 6 FDA requirement for EGFR positivity in the use of anti-EGFR monoclonal antibodies
Track 7 Barriers in conducting clinical trials in colon cancer